K-ras is a member of ras gene family which is involved in cell survival,proliferation and differentiation.When a mutation occurs in ras gene,the activation of Ras proteins may be prolonged to induce oncogenesis.Howeve...K-ras is a member of ras gene family which is involved in cell survival,proliferation and differentiation.When a mutation occurs in ras gene,the activation of Ras proteins may be prolonged to induce oncogenesis.However,the relationship between K-ras mutation and clinical outcomes in pancreatic cancer patients treated with chemotherapy agents is still under debate.In this study,we constructed five pAcGFP1-C3 plasmids for different types of K-ras gene(WT,G12V,G12R,G12D,and G13D)and stably transfected human pancreatic cancer Bxpc-3 cells with these genes.The wild type and mutant clones showed a comparable growth and expression of K-Ras-GFP fusion protein.The expression of some K-ras mutations resulted in a reduced sensitivity to gefitinib,5-FU,docetaxel and gemcitabine,while showed no effects on erlotinib or cisplatin.Moreover,compared with the wild type clone,K-Ras downstream signals(phospho-Akt and/or phospho-Erk)were increased in K-ras mutant clones.Interestingly,different types of K-ras mutation had non-identical K-Ras downstream signal activities and drug responses.Our results are the first to reveal the relationship between different K-ras mutation and drug sensitivities of these anti-cancer drugs in pancreatic cancer cells in vitro.展开更多
The authors presented an efficient method for the palladium-catalyzed Suzuki cross-coupling reaction with the simultaneous reduction of the aldehyde to a hydroxymethyl group.This method allows halide substituted aryl ...The authors presented an efficient method for the palladium-catalyzed Suzuki cross-coupling reaction with the simultaneous reduction of the aldehyde to a hydroxymethyl group.This method allows halide substituted aryl aldehydes to readily react with arylboronic acids,producing polycyclic aromatic alcohols in moderate to good yields.The reaction was catalyzed by Pd（OAc）2（3％,molar fraction） at 150 ℃ in the presence of 6％（molar fraction）1,4-diazabicyclo[2.2.2]octane（DABCO） and 3 times the molecular weight of K2CO3 in the mixture solvent of N,N-dimethylformamide（DMF）/H2O [V（DMF）∶ V（H2O）=5∶1].展开更多
基金supported by National Natural Science Foundation of China(81102459)the Fundamental Research Funds for the Central Universities,Key Laboratory for the Chemistry and Molecular Engineering of Medicinal Resources(Guangxi Normal University)+1 种基金Ministry of Education of China(CMEMR2012-B07)Doctoral Fund of Ministry of Education of China(20130071110069)
文摘K-ras is a member of ras gene family which is involved in cell survival,proliferation and differentiation.When a mutation occurs in ras gene,the activation of Ras proteins may be prolonged to induce oncogenesis.However,the relationship between K-ras mutation and clinical outcomes in pancreatic cancer patients treated with chemotherapy agents is still under debate.In this study,we constructed five pAcGFP1-C3 plasmids for different types of K-ras gene(WT,G12V,G12R,G12D,and G13D)and stably transfected human pancreatic cancer Bxpc-3 cells with these genes.The wild type and mutant clones showed a comparable growth and expression of K-Ras-GFP fusion protein.The expression of some K-ras mutations resulted in a reduced sensitivity to gefitinib,5-FU,docetaxel and gemcitabine,while showed no effects on erlotinib or cisplatin.Moreover,compared with the wild type clone,K-Ras downstream signals(phospho-Akt and/or phospho-Erk)were increased in K-ras mutant clones.Interestingly,different types of K-ras mutation had non-identical K-Ras downstream signal activities and drug responses.Our results are the first to reveal the relationship between different K-ras mutation and drug sensitivities of these anti-cancer drugs in pancreatic cancer cells in vitro.
基金Supported by the Basic Research and Development Program of China（No.2011CB512005） and the National Natural Science Foundation of China（Nos.21362002, 41206077, 81260472）.
文摘The authors presented an efficient method for the palladium-catalyzed Suzuki cross-coupling reaction with the simultaneous reduction of the aldehyde to a hydroxymethyl group.This method allows halide substituted aryl aldehydes to readily react with arylboronic acids,producing polycyclic aromatic alcohols in moderate to good yields.The reaction was catalyzed by Pd（OAc）2（3％,molar fraction） at 150 ℃ in the presence of 6％（molar fraction）1,4-diazabicyclo[2.2.2]octane（DABCO） and 3 times the molecular weight of K2CO3 in the mixture solvent of N,N-dimethylformamide（DMF）/H2O [V（DMF）∶ V（H2O）=5∶1].
